We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

National Lymphangioleiomyomatosis Registry, France (RE-LAM-CE)

This study is currently recruiting participants.
Verified February 2017 by Vincent COTTIN, Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Sponsor:
ClinicalTrials.gov Identifier:
NCT01484236
First Posted: December 2, 2011
Last Update Posted: February 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Hospices Civils de Lyon
Information provided by (Responsible Party):
Vincent COTTIN, Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
  Purpose

RE-LAM-CE is a registry of lymphangioleiomyomatosis cases in France. its aim is to determine the incidence and prevalence of lymphangioleiomyomatosis in France, including demographic information and information concerning the timing and modalities of diagnosis.

Based on the registry, we will set up a prospective cohort of patients. The database will include detailed medical information, particularly regarding progression of the respiratory function.


Condition
Lymphangioleiomyomatosis

Study Type: Observational
Study Design: Observational Model: Other
Time Perspective: Cross-Sectional
Official Title: National Lymphangioleiomyomatosis Registry, France

Resource links provided by NLM:


Further study details as provided by Vincent COTTIN, Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires:

Primary Outcome Measures:
  • Number of cases [ Time Frame: 4 years ]
    Determine incidence and prevalence of lymphangioleiomyomatosis.


Secondary Outcome Measures:
  • localisation of cases [ Time Frame: 4 years ]
    Estimate the proportion of patients with lymphangioleiomyomatosis who are managed by the Reference Center and Centers of excellence for rare lung diseases in France (coverage rate of centers)

  • Progression-free survival [ Time Frame: 4 years ]
    Determine the frequency of the various forms with mild to moderate or severe, and rapid or slow evolution.

  • Progression-free survival [ Time Frame: 4 years ]
    Determine applicability of diagnostic criteria proposed in 2009


Estimated Enrollment: 200
Study Start Date: January 2012
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Detailed Description:

Lymphangioleiomyomatosis is a rare pulmonary disease occuring preferentially in women. Few data are available regarding the epidemiology of this disease, the frequency of the various forms with mild to moderate or severe disease, and the rapid or slow progression.

Several sources of information will be used in order to increase completeness. The registry will also allow to estimate the proportion of patients with lymphangioleiomyomatosis who are managed by the Reference Center and Competence Centers for rare lung diseases in France.

Data will be collected by a research assistant, and the study will be coordinated by the Pole IMER - Department of Public health and Epidemiology of HCL (Lyon Hospitals).

This study will provide a better knowledge on the natural course of the disease and the variability in severity and progression of lymphangioleiomyomatosis, and the applicability of diagnostic criteria proposed in 2009. This study will provide the first detailed epidemiological information on Lymphangioleiomyomatosis, will assess the management of this rare disease within the French National Plan for rare diseases 2005 - 2009, and will provide valuable medical information prior to the establishment of clinical trials

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with lymphangioleiomyomatosis
Criteria

Inclusion Criteria:

  • Patients with sporadic lymphangioleiomyomatosis or associated with Tuberous sclerosis.
  • patients diagnosed or hospitalized or seen in consultation since 01/01/2008

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01484236


Contacts
Contact: Vincent Cottin, MD 33-472-357-072
Contact: Raphaële Guelminger, CRA 33-472-357-074

Locations
France
Hôpital Louis Pradel Recruiting
Lyon (Bron), France, 69677
Contact: Vincent Cottin, MD    33-472-357-072    vincent.cottin@chu-lyon.fr   
Contact: Raphaële Guelminger, CRA    33-472-357-074    registre.lam@gmail.com   
Sponsors and Collaborators
Vincent COTTIN
Hospices Civils de Lyon
Investigators
Principal Investigator: Vincent Cottin, MD Groupe d'Etudes et de Recherche sur les Maladie Orpheline
  More Information

Responsible Party: Vincent COTTIN, Professor V. Cottin, Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
ClinicalTrials.gov Identifier: NCT01484236     History of Changes
Other Study ID Numbers: GERMOP-003
First Submitted: November 30, 2011
First Posted: December 2, 2011
Last Update Posted: February 23, 2017
Last Verified: February 2017

Keywords provided by Vincent COTTIN, Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires:
Lymphangioleiomyomatosis

Additional relevant MeSH terms:
Lymphangioleiomyomatosis
Lymphangiomyoma
Lymphatic Vessel Tumors
Neoplasms by Histologic Type
Neoplasms
Perivascular Epithelioid Cell Neoplasms
Neoplasms, Connective and Soft Tissue
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases